---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-007816"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:56:38.619124+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Q4 2024 revenue $44M (+26% YoY); net loss improves to $(108)M; 2025 rev guidance $160-180M

## Summary
- Q4 total revenue $44M (up 26% YoY); Cell Engineering rev $35M (+29% YoY), Biosecurity $9M.
- GAAP net loss $(108)M vs $(212)M in Q4 2023; Adj EBITDA $(57)M vs $(101)M.
- Cash flow $(55)M in Q4, improved from $(114)M in Q3; cash balance $562M.
- FY2025 guidance: total revenue $160-180M, Cell Engineering $110-130M, Biosecurity at least $50M.
- Cost-cutting achieved $190M annualized run-rate savings; targeting $250M by Q3 2025.

## SEC filing metadata
- accession: 0001628280-25-007816
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000162828025007816/0001628280-25-007816-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000162828025007816/dna-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-007816
- JSON: https://secwatch.observer/filing/0001628280-25-007816.json
- Plain text: https://secwatch.observer/filing/0001628280-25-007816.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.